Related Experiment Video

Updated: Jan 10, 2026

Detecting Anastasis In Vivo by CaspaseTracker Biosensor
20:16

Detecting Anastasis In Vivo by CaspaseTracker Biosensor

Published on: February 1, 2018

9.7K

Risk of Childhood Cancer in Children with Congenital Anomalies and Their Impact on Survival: A Population-Based

Carmen Martos1, Laura García-Villodre1, Laia Barrachina-Bonet1

  • 1Rare Diseases Research Unit, Foundation for the Promotion of Health and Biomedical Research of the Valencian Region (Fisabio), 46020 Valencia, Spain.

Current Oncology (Toronto, Ont.)
|November 26, 2025
PubMed

Insights

Childhood cancer survivors face long-term health issues and increased early death risks due to chronic conditions. This highlights the need for ongoing monitoring and specialized care for these individuals.

Area of Science:

  • Pediatric Oncology
  • Long-term Health Outcomes
  • Survivorship Care

Background:

  • Childhood cancer treatment advances have improved survival rates.
  • Survivors often experience significant chronic health conditions.
  • These conditions increase the risk of premature mortality.

Purpose of the Study:

  • To summarize the long-term health challenges faced by childhood cancer survivors.
  • To emphasize the elevated mortality risk in this population.
  • To underscore the importance of specialized survivorship care.

Main Methods:

  • Literature review of studies on childhood cancer survivorship.
  • Analysis of data on comorbidities and mortality rates.
  • Synthesis of findings on treatment sequelae.

Main Results:

  • Childhood cancer survivors experience a high burden of chronic health conditions.
  • These comorbidities significantly elevate the risk of premature death.
  • Long-term adverse effects of cancer treatment persist.

Conclusions:

  • Childhood cancer survivorship requires comprehensive, long-term management.
  • Addressing chronic health conditions is crucial for improving outcomes.
  • Specialized care is essential to mitigate risks and enhance quality of life.

Keywords:
childhood cancer riskchildhood cancerscongenital anomaliespopulation-based registriessurvival

More Related Videos

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.9K
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

631

Related Concept Videos

Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
7.6K
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
633
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.8K
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
3.9K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
387
Mismatch Repair01:20

Mismatch Repair

Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
6.3K